Nureca Q2 FY27: revenue up 55% YoY, margin compression caps PAT growth at 12%

Nureca's consolidated (primary) revenue for Q2 FY27 came in at ₹58.53 Cr, up 55.1% YoY from ₹37.74 Cr and up 45.1% QoQ from ₹40.34 Cr — a sharp acceleration in the home-healthcare products business. But consolidated PAT from continuing operations grew only 11.7% YoY to ₹4.05 Cr (₹3.63 Cr a year ago), even as it jumped 32.1% QoQ (₹3.07 Cr) — the QoQ pop is not the headline because YoY profit growth trails YoY revenue growth by a wide margin. Net profit margin compressed to 6.77% from 9.06% a year ago and 7.27% last quarter. No analyst consensus or brokerage preview could be found for this print — coverage is effectively absent for a company this size — so vs-street is unknown; management has also issued no formal guidance on record, so vs-guidance is unknown too. The margin squeeze sits on the cost-of-goods line: net of the inventory build, material-related costs (purchase of stock-in-trade less the change in inventories) rose roughly 81% YoY, well ahead of the 55% revenue growth, while employee costs were nearly flat YoY (₹4.11 Cr vs ₹4.17 Cr) and finance costs fell (₹0.26 Cr vs ₹0.46 Cr), so the pressure is specifically a product-cost/mix issue rather than a cost-structure one. Depreciation rose to ₹0.81 Cr from ₹0.54 Cr as the company ramped capex — H1 cash outflow for property, plant, equipment and intangibles was ₹21.40 Cr, with a new ₹5.34 Cr capital-work-in-progress balance appearing on the books, consistent with capacity expansion. Standalone PAT grew a touch faster at 15.4% YoY (₹3.62 Cr vs ₹3.14 Cr) against consolidated's 11.7% — a ~3.7 percentage-point divergence, modest but above the threshold worth flagging; subsidiary-level results (Nureca Technologies, Nureca INC) weighed slightly on the group number without materially changing the picture. On corporate developments, the company closed a DRI (customs) matter this quarter with a ₹0.57 Cr pre-deposit appropriated to settle it — a resolved legal overhang rather than a fresh charge visible as a separate P&L line. Promoter and MD Saurabh Goyal made several open-market purchases through late September and early October 2026, after the trading window closed around the results date — a demonstrated-confidence signal that sits alongside, but is not proof of, the quarter's numbers. No management press release accompanied this filing, so there is no standalone management commentary to cross-check against the print beyond the audited statement and the limited-review auditor's notes, which raised no qualifications.